GlassScriptPhysician profile
Gregory D Sambuchi
NPI 1942203112
$36,573.79
in general payments reported to CMS, 2019-2025
67 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $8,225 · 2021: $1,952 · 2022: $2,205 · 2023: $2,221 · 2024: $1,473 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,880 · Education: $58.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,879.62 |
| Education | $58.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $17,584.03 | 2019-2025 | |
| Allergan, INC. | $6,196.77 | 2020-2022 | |
| Abbvie INC. | $1,446.05 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $1,420.99 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Ucb, INC. | $935.98 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Sk Life Science, INC. | $638.33 | 2020-2025 | |
| Amgen INC. | $604.90 | 2019-2025 | Uplizna, Aimovig |
| Lundbeck LLC | $604.11 | 2019-2025 | Vyepti, Rexulti |
| Supernus Pharmaceuticals, INC. | $465.03 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $407.31 | 2019-2025 | Rytary, Ongentys |
| Neurocrine Biosciences, INC. | $364.13 | 2020-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $347.01 | 2019-2025 | |
| Livanova USA, INC. | $299.13 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Mdd US Operations, LLC | $280.82 | 2019-2024 | Gocovri |
| Neurelis, INC. | $273.13 | 2021-2024 | Valtoco |
Show all 66 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$255,931.15 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Sambuchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.